Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2008-05-13
2008-05-13
Campell, Bruce R. (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C424S208100, C435S069100, C435S235100, C435S320100
Reexamination Certificate
active
07371846
ABSTRACT:
The invention relates to novel CD4-independent HIV Envelope proteins and uses therefor.
REFERENCES:
patent: 4160452 (1979-07-01), Theeuwes
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 5614612 (1997-03-01), Haigwood et al.
patent: 5691135 (1997-11-01), Braun et al.
patent: 5741492 (1998-04-01), Hurwitz et al.
patent: 5864027 (1999-01-01), Berman et al.
patent: 5871732 (1999-02-01), Burkly et al.
patent: 6001977 (1999-12-01), Chang et al.
patent: 6420545 (2002-07-01), Hoxie et al.
patent: 6849261 (2005-02-01), Hoxie et al.
patent: 0 552 850 (1985-10-01), None
patent: 94/17810 (1994-08-01), None
patent: 94/23744 (1994-10-01), None
Bowie et al (1990) Science. 247: 1306-1310.
Alexander, W. et al., “Regulated Expression of Foreign Genes in Vaccinia Virus Under the Control of Bacteriophage T7 RNA Polymerase and theEscherichia coliLac Repressor,”Journal of Virology, vol. 66, pp. 2934-2942, American Society for Microbiology, 1992.
Alkhatib, G. et al., CC CKR5: a RANTES, MIP-1α, MIP-1β Receptor as a Fusion Cofactor for Macrophage-Tropic HIF-1,Sciencevol. 272, pp. 1955-1958, 1998.
Bandres, J. C. et al., “Human Immunodeficiency Virus (HIV) Envelope Binds to CXCR4 Independently of CD4, and Binding Can be Enhanced by Interaction With Soluble CF4 or by HIV Envelope Deglycosylation,”Journal Virol., vol. 72, pp. 2500-2504, 1998.
Berger, E. A. et al., “HIV Entry and Tropism: The Chemokine Receptor Connection,”AIDS, vol. 11, pp. S3-S16, 1997.
Bird, R. E. et al., “Single-Chain Antigen-Binding Proteins,”Science, vol. 242, pp. 423-426, 1988.
Bork, P., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,”Genome Research, vol. 10, pp. 398-400, Cold Spring Harbor Laboratory Press, 2000.
Burger, S. R. et al., “Stable Expression of Rabies Virus Glycoprotein in Chinese Hamster Ovary Cells,”General Virology, vol. 72, pp. 359-367, printed in Great Britain, 1991.
Burton, D. R. et al., “The Antibody Response in HIV-1 Infection,”AIDS, 1997, (suppl. A), vol. 11, pp. S87-S98, Rapid Science Publishers, 1997.
Cao, J. et al., “Effects of Amino Acid Changes in the Extracellular Domain of the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein,”J. Virol., vol. 67, pp. 2747-2755, 1993.
Cao, J. et al., “Replication and Neutralization of Human Immunodeficiency Virus Type 1 Lacking the V1 and V1 Variable Loops of the gp120 Envelope Glycoprotein,”J. Virol., vol. 71, pp. 9808-9812, 1997.
Chackerian, B. et al., “Human Immunodeficiency Virus Type 1 Coreceptors Participate in Postentry Stages in the Virus Replication Cycle and Function in Simian Immunodeficiency Virus Infection,”Journal of Virology, vol. 71, pp. 3932-3939, 1997, American Society for Microbiology.
Chan, D. C. et al., “Core Structure of gp41 From the HIV Envelope Glycoprotein,”Cell, vol. 89, pp. 263-273, 1997.
Chen, S. S., et al:, “Characterization of an Envelope Mutant of HIV-1 That Interferes With Viral Infectivity,”Virology, vol. 226, pp. 260-268, 1996.
Cho, M. et al., “Identification of Determinants on a Dualtropic Human Immunodeficiency Virus Type 1 Envelope Glycoprotein That Confer Usage of CXCR4,”Journal of Virology, vol. 72, pp. 2509-2515, 1998.
Choe, H. et al., “The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates,”Cells, vol. 85, pp. 1135-1148, 1996.
Cocchi, F. et al., “The V3 Domain of the HIV-1 gp120 Envelope Glycoprotein is Critical for Chemokine Mediated Blockade of Infection,”Nature Medicine, vol. 2, No. 11, pp. 1244-1247, 1996.
Connor, Ruth I. et al., “Vpr is Required for efficient Replication of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes,”Virology. vol. 206, pp. 935-944, 1995.
Connor, R. et al., “Change in Coreceptor use Coreceptor use Correlates With Disease Progression in HIV-1 Infected Individuals,”Journal Exp. Med., vol. 185, pp. 621-628, 1997.
Cranage, M. P. et al., “Identification of the Human Cytomegalovirus glycoprotein B Gene and Induction of Neutralizing Antibodies via its Expression in Recombinant Vaccinia Virus,”The EMBO Journal, vol. 5, No. 11, pp. 3057-3063, Press Limited, Oxford, England, 1986.
Deng, H. et al., “Expression Cloning of New Receptors Used by Simian and Human Immunodeficiency Viruses,”Nature, (London), vol. 388, pp. 296-300, 1997.
Deng, H. et al., “Identification of a Major Co-Receptor for Primary Isolates of HIV-1,”Nature, (London), vol. 381, pp. 661-666, 1996.
Doranz, B. et al., “A Dual Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3 and CKR-2b as Fusion Cofactors.,”Cell, vol. 85, pp. 1149-1158, 1996.
Doranz, B. J. et al., “A Small-molecule Inhibitor Directed Against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor,”J. Exp Med., vol. 186, No. 8, pp. 1395-1400, The Rockefeller University Press, 1997.
Doranz et al., “Identification of CXCR4 Domains That Support Coreceptor and Chemokine Receptor functions,”Journal of Virology, vol. 73, No. 4, pp. 2752-2761, 1999.
Dragic, T et al., “HIV-1 Entry Into CD4+ Cells is Mediated by the Chemokine Receptor CC-CKR-5,”Nature, vol. 381, pp. 667-673, 1996.
Dubay, J. W. et al., “Trucation of the Human Immunodeficiency Virus Type 1 Transmemebrane Glycoprotein Cytoplasmic Domain Blocks Virus Infectivity,”J. Virol., vol. 72, pp. 6616-6625, 1992.
Dumonceaux, J. et al., “Spontaneous Mutations in theenvGene of the Human Immunodeficiency Virus Type 1 NDK Isolate are Associated with a CD4-Independent Entry Phenotype,”Journal Virol., vol. 72, No. 1, pp. 512-519, 1998.
Earl, P. L. et al., “Epitope Map of Human Immunodeficiency Virus Type 1 gp41 Derived From 47 Monoclonal Antibodies Produced by Immunization with Oligomeric Envelope Protein,”J. Virol., vol. 71, No. 4, pp. 2674-2684, 1997.
Edinger, A. L. et al., “CD4-Independent, CCR5-Dependent Infection of Brain Capillary Endothelial Cells by a Neurovirulent SIV Strain,”Proc. Natl. Acad. Sci., USA, vol. 94, pp. 14742-14747, 1997.
Edwards, T. G. et al., “Relationships Between CD4 Independence, Neutralization Sensitivity, and Exposure of a CD4-Induced Epitope in a Human Immunodeficiency Virus Type 1 Envelope Protein,”Journal of Virology, vol. 75, No. 11, pp. 5230-5239, 2001, American Society for Microbiology.
Endres, M. J. et al., “CD4-Independent Infection by HIV-2 is Mediated by Fusin/CXCR4,”Cell, vol. 87, pp. 745-756, 1996.
Endres, M. J. et al., “Targeting of HIV-and SIV-Infected Cells by CD4-Chemokine Receptor Pseudotypes,”Science, vol. 278, pp. 1462-1464, 1997.
Farzan, M. et al., “Two Orphan Seven-Transmembrane Segment Receptors Which are Expressed in CD-4-Positive Cells Support Simian Immunodeficiency Virus Infection,”Journal Exp. Medical, vol. 186, pp. 405-411, 1997.
Feng, Y. et al., “HIV-I Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor,”Science, vol. 272, pp. 872-876, 1996.
Gibbs, J. S. et al., “Construction and In Vitro Properties of HIV-1 Mutants With Deletions in “Nonessential” Genes,”Aids Research and Human Retroviruses, vol. 10, No. 4, pp. 343-350, 1994.
Haigwood, N. L. et al., “Characterization of Group Specific Antibodies in Primates: Studies With SIV Envelope in Macaques,”J. Med. Primatol., vol. 21, pp. 82-90, 1992.
Hesselgesser, J. et al., “CD4-Independent Association Between HIV-1 gp120 and CXCR4: Functional Chemokine Receptors are Expressed in Human Neurons,”Curr. Biol., vol. 7, pp. 112-121, 1997.
Hill, M. et al., “Envelope Glycoproteins From Human Immunodeficiency Virus Types 1 and 2 and Simian Immunodeficiency Virus can use Human CCR5 as a Coreceptor for Viral Entry a
Doms Robert W.
Hoffman Trevor L.
Hoxie James A.
LaBranche Celia C.
Campell Bruce R.
Drinker Biddle & Reath
Horning Michelle
The Trustees of the University of Pennsylvania
LandOfFree
CD4-independent HIV envelope proteins as vaccines and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD4-independent HIV envelope proteins as vaccines and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD4-independent HIV envelope proteins as vaccines and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2796053